The aim of this research was to design and develop chitosan-coated nano-liposomes of progesterone for its safe and effective oral delivery through the vesicular system providing sustained drug release, enhanced drug stability in gastro-intestinal (GI) fluid and improved drug absorption leading to better patient compliance. The aqueous solubility of progesterone (poorly soluble drug) was enhanced by hydroxy-propyl-beta-cyclodextrin complexation and the drug-loaded liposomes were prepared by ethanol injection method followed by surface coating with chitosan. Design of experiment-based formulation optimization was performed using Box-Behnken design selecting lipid, cholesterol, and drug content as formulation factors (independent variables) and mean particle size (MPS), polydispersity index (PDI), zeta potential (ZP), entrapment efficiency (EE), drug loading (DL) and cumulative % drug release (CDR) as evaluation parameters (response variables). The optimized formulation was prepared and evaluated for all preferred critical quality attributes which showed 168.3 nm MPS, 0.307 PDI, 24 mV ZP, 53% EE, 7.2% DL, and 76.4% CDR at 24 hours. In-vitro GI drug stability of chitosan-coated liposomes was studied in simulated gastric fluid and simulated intestinal fluid which exhibited 2.12 and 77.3 fold extended half-life, respectively. The ex-vivo GI-drug absorption study demonstrated two-fold rise in progesterone absorption from liposomal formulation. The chitosan-coated liposomes of progesterone which showed sustained drug release following Higuchi model kinetics was found to be a better alternative for oral delivery of progesterone overcoming drawbacks of conventional dosage forms.
Dehariya P, Soni R, Paswan SK, Soni PK. Design of experiment based formulation optimization of chitosan-coated nano-liposomes of progesterone for effective oral delivery. J Appl Pharm Sci, 2023; 13(06):256–270. https://doi.org/10.7324/JAPS.2023.142351
Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, Samiei M, Kouhi M, Nejati-Koshki K. Liposome: classification, preparation, and applications. Nanoscale Res Lett, 2013; 8:102. https://doi.org/10.1186/1556-276X-8-102 | |
Alqahtani MS, Kazi M, Alsenaidy MA, Ahmad MZ. Advances in oral drug delivery. Front Pharmacol, 2021; 12:618411. https://doi.org/10.3389/fphar.2021.618411 | |
Arafat M, Kirchhoefer C, Mikov M, Sarfraz M, Löbenberg R. Nanosized liposomes containing bile salt: a vesicular nanocarrier for enhancing oral bioavailability of BCS class III drug. J Pharm Sci, 2017; 20:305-18. https://doi.org/10.18433/J3CK88 | |
Babadi D, Dadashzadeh S, Osouli M, Abbasian Z, Daryabari MS, Sadrai S, Haeri A. Biopharmaceutical and pharmacokinetic aspects of nanocarrier-mediated oral delivery of poorly soluble drugs. J Drug Deliv Sci Technol, 2021; 62:102324. https://doi.org/10.1016/j.jddst.2021.102324 | |
Bajka BH, Rigby NM, Cross KL, Macierzanka A, Mackie AR. The influence of small intestinal mucus structure on particle transport ex vivo. Colloids Surf B, 2015; 135:73-80. https://doi.org/10.1016/j.colsurfb.2015.07.038 | |
Braga Emidio N, Tran HNT, Andersson A, Dawson PE, Albericio F, Vetter I, Muttenthaler, M. Improving the gastrointestinal stability of linaclotide. J Med Chem, 2021; 64:8384-90. https://doi.org/10.1021/acs.jmedchem.1c00380 | |
Cagdas M, Sezer, AD, Bucak S. Liposomes as potential drug carrier systems for drug delivery. InTech Open, Paris, France, 2014. https://doi.org/10.5772/58459 | |
Chadha R, Bhandari S. Drug-excipient compatibility screening- role of thermoanalytical and spectroscopic techniques. J Pharm Biomed Anal, 2014; 87:82-97. https://doi.org/10.1016/j.jpba.2013.06.016 | |
Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A, Khorasani S, Mozafari MR. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics, 2018; 10(2):57. https://doi.org/10.3390/pharmaceutics10020057 | |
Elsayad MK, Mowafy HA, Zaky AA, Samy AM. Chitosan caged liposomes for improving oral bioavailability of rivaroxaban: in vitro and in vivo evaluation. Pharm Dev Technol, 2021; 26:316-27. https://doi.org/10.1080/10837450.2020.1870237 | |
Ghassemi S, Haeri A, Shahhosseini S, Dadashzadeh S. Labrasol-enriched nanoliposomal formulation: novel approach to improve oral absorption of water-insoluble drug, carvedilol. AAPS PharmSciTech, 2018; 19:2961-70. https://doi.org/10.1208/s12249-018-1118-9 | |
Gouda A, Sakr OS, Nasr M, Sammour O. Ethanol injection technique for liposomes formulation: an insight into development, influencing factors, challenges and applications. J Drug Deliv Sci Technol, 2021; 61:102174. https://doi.org/10.1016/j.jddst.2020.102174 | |
Hasan M, Jahan I, Hasan AHM, Zaman M, Hamiduzzaman M. Formulation development, characterization and in-vitro evaluation of tamoxifen loaded liposomes. J Pharm Res Int, 2020; 32:64-82. https://doi.org/10.9734/jpri/2020/v32i630449 | |
He H, Lu Y, Qi J, Zhu Q, Chen Z, Wu W. Adapting liposomes for oral drug delivery. Acta Pharm Sin B, 2019; 9:36-48. https://doi.org/10.1016/j.apsb.2018.06.005 | |
Homayun B, Lin X, Choi HJ. Challenges and recent progress in oral drug delivery systems for biopharmaceuticals. Pharmaceutics, 2019; 11:129. https://doi.org/10.3390/pharmaceutics11030129 | |
Jaafar-Maalej C, Diab R, Andrieu V, Elaissari A, Fessi H. Ethanol injection method for hydrophilic and lipophilic drug-loaded liposome preparation. J Liposome Res, 2010; 20:228-43. https://doi.org/10.3109/08982100903347923 | |
Jansook P, Loftsson T. CDs as solubilizers: effects of excipients and competing drugs. Int J Pharm, 2009; 379:32-40. https://doi.org/10.1016/j.ijpharm.2009.06.005 | |
Jin Y, Wen J, Garg S, Liu D, Zhou Y, Teng L, Zhang W. Development of a novel niosomal system for oral delivery of ginkgo biloba extract. Int J Nanomed, 2013; 8:421-30. https://doi.org/10.2147/IJN.S37984 | |
Kulkarni SB, Betageri GV, Singh, M. Factors affecting microencapsulation of drugs in liposomes. J Microencapsul, 1995; 12: 229-46. https://doi.org/10.3109/02652049509010292 | |
Lahiani-Skiba M, Barbot C, Bounoure F, Joudieh S, Skiba M. Solubility and dissolution rate of progesterone-cyclodextrin-polymer systems. Drug Dev Ind Pharm, 2006; 32:1043-58. https://doi.org/10.1080/03639040600897093 | |
Large DE, Abdelmessih RG, Fink EA, Auguste DT. Liposome composition in drug delivery design, synthesis, characterization, and clinical application. Adv Drug Deliv Rev, 2021; 176:113851. https://doi.org/10.1016/j.addr.2021.113851 | |
Lee MK. Liposomes for enhanced bioavailability of water-insoluble drugs: in vivo evidence and recent approaches. Pharmaceutics, 2020; 12:264. https://doi.org/10.3390/pharmaceutics12030264 | |
Liu W, Ye A, Han F, Han J. Advances and challenges in liposome digestion: surface interaction, biological fate, and GIT modeling. Adv Colloid Interface Sci, 2019; 263:52-67. https://doi.org/10.1016/j.cis.2018.11.007 | |
Loftsson T, Jarho P, Másson M, Järvinen T. Cyclodextrins in drug delivery. Expert Opin Drug Deliv, 2005; 2:335-51. https://doi.org/10.1517/17425247.2.1.335 | |
Lombardo D, Kiselev MA. Methods of liposomes preparation: formation and control factors of versatile nanocarriers for biomedical and nanomedicine application. Pharmaceutics, 2022; 14:543. https://doi.org/10.3390/pharmaceutics14030543 | |
Luo Z, Paunovi? N, Leroux JC. Physical methods for enhancing drug absorption from the gastrointestinal tract. Adv Drug Deliv Rev, 2021; 175:113814. https://doi.org/10.1016/j.addr.2021.05.024 | |
Ma B, Wang J, Sun J, Li M, Xu H, Sun G, Sun X. Permeability of rhynchophylline across human intestinal cell in vitro. Int J Clin Exp Pathol, 2014; 7:1957-66. | |
Nguyen TX, Huang L, Gauthier M, Yang G, Wang Q. Recent advances in liposome surface modification for oral drug delivery. Nanomedicine, 2016; 11:1169-85. https://doi.org/10.2217/nnm.16.9 | |
Nguyen TX, Huang L, Liu L, Elamin Abdalla AM, Gauthier M, Yang G. Chitosan-coated nano-liposomes for the oral delivery of berberine hydrochloride. J Mater Chem B, 2014; 2:7149-59. https://doi.org/10.1039/C4TB00876F | |
Panwar P, Pandey B, Lakhera PC, Singh KP. Preparation, characterization, and in vitro release study of albendazole-encapsulated nanosize liposomes. Int J Nanomed, 2010; 5:101-8. https://doi.org/10.2147/IJN.S8030 | |
Schwendener RA, Schott H. Liposome formulations of hydrophobic drugs. Mçethods Mol Biol, 2010; 605:129-38. https://doi.org/10.1007/978-1-60327-360-2_8 | |
Sharma S, Diwan A, Kalra R, Arora V. Physico-chemical characterization, analytical method development and solubility studies for progesterone. Indian J Pharm Biol Res, 2017; 5(2):29-35. https://doi.org/10.30750/ijpbr.5.2.6 | |
Shimpi S, Chauhan B, Shimpi P. Cyclodextrins: application in different routes of drug administration. Acta Pharm, 2005; 55:139-56. | |
Simon JA, Robinson DE, Andrews MC, Hildebrand JR 3rd, Rocci ML Jr, Blake RE, Hodgen GD. The absorption of oral micronized progesterone: the effect of food, dose proportionality, and comparison with intramuscular progesterone. Fertil Steril, 1993; 60:26-33. https://doi.org/10.1016/S0015-0282(16)56031-2 | |
Soni PK, Saini TR. Development and evaluation of HP-β-CD complexation based novel ophthalmic gel formulation of nepafenac. Int J Pharm Sci, 2019; 10(12):5707-14. | |
Soni PK, Saini TR. Formulation design and optimization of cationic-charged liposomes of brimonidine tartrate for effective ocular drug delivery by design of experiment (DoE) approach. Drug Dev Ind Pharm, 2021a; 47:1847-66. https://doi.org/10.1080/03639045.2022.2070198 | |
Soni PK, Saini TR. Purification of drug loaded liposomal formulations by a novel stirred cell ultrafiltration technique. Pharm Nanotechnol, 2021b; 9:347-360. https://doi.org/10.2174/2211738509666211124145848 | |
Stanczyk FZ, Hapgood J, Winer S, Mishell DRJr. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev, 2013; 34:171-208. https://doi.org/10.1210/er.2012-1008 | |
Sur S, Fries AC, Kinzler KW, Zhou S, Vogelstein, B. Remote loading of preencapsulated drugs into stealth liposomes. Proc Natl Acad Sci USA, 2014; 111:2283-8. https://doi.org/10.1073/pnas.1324135111 | |
Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov, 2005; 4:145-60. https://doi.org/10.1038/nrd1632 | |
Vemuri S, Rhodes CT. Preparation and characterization of liposomes as therapeutic delivery systems: a review. Pharm Acta Helv, 1995; 70:95-111. https://doi.org/10.1016/0031-6865(95)00010-7 | |
Wang M, Liu M, Xie T, Zhang BF, Gao XL. Chitosan-modified cholesterol-free liposomes for improving the oral bioavailability of progesterone. Colloids Surf B, 2017; 159:580-5. https://doi.org/10.1016/j.colsurfb.2017.08.028 | |
Weng J, Tong HHY. In vitro release study of the polymeric drug nanoparticles: development and validation of a novel method. Pharmaceutics, 2020; 12(8):732. https://doi.org/10.3390/pharmaceutics12080732 | |
Zafar A, Alruwaili NK, Imam SS. Formulation of genistein-hp β cyclodextrin-poloxamer 188 ternary inclusion complex: solubility to cytotoxicity assessment. Pharmaceutics, 2021; 13:1997. https://doi.org/10.3390/pharmaceutics13121997 | |
Year
Month
Effects of progesterone and estradiol on the inflammatory and apoptotic markers of ovariectomized rats challenged with acute septic systemic inflammation
Sinan Subhi Farhan, Samir Saad Mahgoub, Saad Abdulrahman HussainNon invasive insulins: advanced insulin therapy over this decade
T. S. RajeswariEnhanced Solubility and Dissolution Rate of Clopidogrel by Nanosuspension: Formulation via High Pressure Homogenization Technique and Optimization Using Box Behnken Design Response Surface Methodology